Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.53 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.47 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.45 |
| ▸ | TYMS | P04818 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
| ▸ | S100A4 | P26447 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6212303 | 0.88 | METAP1 (0.50) | METAP1SRD5A1SRD5A2PARP10PARP11 | |
| SCHEMBL31268305 | 0.84 | SRD5A1 (0.64) | METAP1SRD5A1SRD5A2PARP10PARP11 | |
| SCHEMBL204100 | 0.84 | SRD5A1 (0.64) | METAP1SRD5A1SRD5A2PARP10PARP11 | |
| SCHEMBL29914776 | 0.83 | TDP1 (0.52) | METAP1SRD5A1SRD5A2PARP10PARP11 | |
| SCHEMBL3362722 | 0.83 | TDP1 (0.52) | METAP1SRD5A1SRD5A2PARP10PARP11 | |
| SCHEMBL4817935 | 0.79 | SRD5A1 (0.60) | METAP1SRD5A1SRD5A2PARP10PARP11 | |
| SCHEMBL17802121 | 0.77 | METAP1 (0.45) | METAP1SRD5A1SRD5A2PARP10PARP11 | |
| SCHEMBL20797143 | 0.77 | SRD5A1 (0.57) | METAP1SRD5A1SRD5A2PARP10PARP11 | |
| SCHEMBL20797150 | 0.77 | SRD5A1 (0.57) | METAP1SRD5A1SRD5A2PARP10PARP11 | |
| SCHEMBL20797234 | 0.77 | SRD5A1 (0.57) | METAP1SRD5A1SRD5A2PARP10PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4426287-A1 | ALPHA-2A ADRENERGIC RECEPTOR MODULATORS AND USES THEREOF | The Regents of the University of California (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2024109919-A1 | PYRIDONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 盛睿泽华医药科技（苏州）有限公司 | 2024-05-30 | — | — | WO | disclosed |
| WO-2023081800-A1 | ALPHA-2A ADRENERGIC RECEPTOR MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2022212194-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2017109061-A1 | SPIROCYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | IEO - ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017109061-A1 | SPIROCYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | IEO - ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2017-06-29 | — | — | WO | disclosed |
| US-7259183-B2 | Indole, indazole and indoline derivatives as CETP inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-20070135433-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | DEAN DAVID K | 2007-06-14 | — | — | US | disclosed |
| EP-1776338-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| US-7199137-B2 | Imidazole derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2007-04-03 | — | — | US | disclosed |
| WO-2007033002-A1 | CONFORMATIONALLY CONSTRAINED 3- (4-HYDROXY-PHENYL) - SUBSTITUTED-PROPANOIC ACIDS USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2006013048-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | CETP, NAT1, MTTP | METAP1 59/4885SRD5A1 196/4885SRD5A2 580/4885 |
| US-20070135433-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | METAP1 3407/4885SRD5A1 4616/4885SRD5A2 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.